Chargement en cours...

First line treatment of metastatic renal cell carcinoma: Two standards with different toxicity profile

Tyrosine kinase inhibitors are de facto the more used targeted therapies for upfront treatment of metastatic renal cell carcinoma (mRCC). Among these, sunitinib and pazopanib have reported greater activity in term of progression-free survival and overall survival compared with interferon-α or placeb...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Iacovelli, Roberto, Verzoni, Elena, De Braud, Filippo, Procopio, Giuseppe
Format: Artigo
Langue:Inglês
Publié: Landes Bioscience 2014
Sujets:
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC3938518/
https://ncbi.nlm.nih.gov/pubmed/24253418
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4161/cbt.27150
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!